Abstract
Individuals with intellectual and/or developmental disability (IDD) are often co-prescribed antipsychotic medications (APs). However, despite their known propensity to cause metabolic adverse effects including weight gain, diabetes, and increased risk of cardiovascular events, there is currently a limited body of literature describing the metabolic consequences of AP use in individuals with IDD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
